Pembrolizumab Shows Lasting Cancer Benefits
Pembrolizumab has demonstrated lasting benefits in two key cancer trials. The NEOPRISM-CRC trial recorded zero relapses in intestinal cancer 33 months post-pre-surgical treatment. These findings were presented at ASCO 2026.
Topics
Developing
- 880d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 880d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 880d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 880d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Mastodon
“Pembrolizumab muestra beneficios duraderos en dos ensayos clave contra el cáncer. El NEOPRISM-CRC registró cero recaídas en cáncer de intestino 33 meses post-tratamiento pre-quirúrgico. En ASCO 2026,”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade